The biopharma announced full-year 2018 operating results.
News & Analysis: Jounce Therapeutics, Inc.
The early-stage company's lead drug candidate disappointed in a phase 1/2 study.
All your Motley Fool coverage of the 2018 ASCO Conference in one place.
The clinical-stage upstart reported disappointing news that sparked pessimism.
Find out which of these stocks fell because of earnings concerns.
Shares of Jounce Therapeutics and Sangamo Therapeutics were both hit hard last week by the marketwide sell-off. This dip is likely to prove temporary in both cases, however.
Investors should find out if Jounce's lead drug candidate could be a winner.
Celgene appears to have lit a fire beneath all three of these small biotech stocks.
Depending on data later this year, Celgene may want to buy this collaboration partner.
Data from a small-cap biotech stock that's working with Celgene on a new approach to cancer treatment is expected in 2018.